deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03011372

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

Sponsor: Incyte Corporation

Conditions MPN (Myeloproliferative Neoplasms)
Interventions Pemigatinib
Updated 30 times since 2017 Last updated: Nov 4, 2025 Started: Apr 25, 2017 Primary completion: Oct 30, 2024 Completion: Oct 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03011372, this PHASE2 trial focuses on MPN (Myeloproliferative Neoplasms) and remains completed. Sponsored by Incyte Corporation, it has been updated 30 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Sep 2017 · 6 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Jun 2020 · 8 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Aug 2025 · 8 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

30 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2

  4. Dec 2024 — Aug 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Oct 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 25 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  8. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  9. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  10. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE2

  11. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  12. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  13. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  14. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  15. Oct 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  16. May 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  17. Nov 2018 — May 2019 [monthly]

    Recruiting PHASE2

  18. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  19. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  20. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  21. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  22. Oct 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  23. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  24. Mar 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Feb 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Atlanta, United States , Bergamo, Italy , Bern, Switzerland , Duarte, United States , Florence, Italy , Halle, Germany , Houston, United States , Indianapolis, United States , Jena, Germany and 22 more locations